[Immunogenicity of biopharmaceuticals. Experiences with beta-interferon, EPO and anti-TNF].
Bendtzen
Klaus
K
Institut for Inflammationsforskning, Finsencentret, H:S Rigshospitalet, DK-2100 København ø. kben@mail.dk
D000818:Animals; D000917:Antibody Formation / Q000235:genetics / Q000276:immunology; D004921:Erythropoietin / Q000009:adverse effects / Q000235:genetics / Q000276:immunology*; D006801:Humans; D007155:Immunologic Factors / Q000009:adverse effects / Q000235:genetics / Q000276:immunology*; D016899:Interferon-beta / Q000009:adverse effects / Q000235:genetics / Q000276:immunology*; D011993:Recombinant Fusion Proteins / Q000009:adverse effects / Q000235:genetics / Q000276:immunology*; D014409:Tumor Necrosis Factor-alpha / Q000009:adverse effects / Q000235:genetics / Q000276:immunology*
D007155:Immunologic Factors; D011993:Recombinant Fusion Proteins; D014409:Tumor Necrosis Factor-alpha; D004921:Erythropoietin; D016899:Interferon-beta